Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.
Company profile
Ticker
TENX
Exchange
Website
CEO
Anthony DiTonno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
SEC CIK
Corporate docs
Subsidiaries
Life Newco, Inc. • PHPrecisionMed Inc. ...
IRS number
262593535
TENX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
22 Mar 23
8-K
Termination of a Material Definitive Agreement
10 Feb 23
8-K
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
7 Feb 23
424B4
Prospectus supplement with pricing info
6 Feb 23
EFFECT
Notice of effectiveness
3 Feb 23
S-1MEF
Registration of additional securities for an S-1
2 Feb 23
8-K
Patent is expected to provide additional intellectual property protection until 2040
1 Feb 23
CORRESP
Correspondence with SEC
1 Feb 23
S-1/A
IPO registration (amended)
31 Jan 23
UPLOAD
Letter from SEC
26 Jan 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
13 Feb 23
SC 13D/A
Rich Stuart
9 Feb 23
SC 13D/A
Doogan Declan
9 Feb 23
SC 13D/A
Rich Stuart
6 Jan 23
SC 13D/A
Doogan Declan
6 Jan 23
SC 13D/A
Rich Stuart
23 Sep 22
4
Stuart Rich
23 Sep 22
SC 13D/A
Doogan Declan
12 Aug 22
4
Declan Doogan
12 Aug 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.81 mm | 3.81 mm | 3.81 mm | 3.81 mm | 3.81 mm | 3.81 mm |
| Cash burn (monthly) | 1.14 mm | 378.97 k | (no burn) | (no burn) | 1.11 mm | 1.04 mm |
| Cash used (since last report) | 6.59 mm | 2.19 mm | n/a | n/a | 6.42 mm | 6.01 mm |
| Cash remaining | -2.79 mm | 1.62 mm | n/a | n/a | -2.61 mm | -2.20 mm |
| Runway (months of cash) | -2.4 | 4.3 | n/a | n/a | -2.4 | -2.1 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 28 |
| Opened positions | 8 |
| Closed positions | 6 |
| Increased positions | 6 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 1.58 mm |
| Total shares | 9.05 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Gofen & Glossberg | 3.82 mm | $649.00 k |
| Armistice Capital | 1.97 mm | $334.00 k |
| Stuart Rich | 1.91 mm | $370.00 k |
| BLK Blackrock | 479.07 k | $81.00 k |
| PNC PNC Financial Services | 200.00 k | $34.00 k |
| Vanguard | 173.80 k | $30.00 k |
| Renaissance Technologies | 141.63 k | $24.00 k |
| Millennium Management | 78.83 k | $13.00 k |
| Financial Advisory Service | 58.33 k | $10.00 k |
| Geode Capital Management | 51.21 k | $8.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Sep 22 | Stuart Rich | Common Stock | Gift | Acquire G | Yes | No | 0 | 1,909,585 | 0.00 | 1,909,585 |
| 21 Sep 22 | Stuart Rich | Common Stock | Gift | Dispose G | No | No | 0 | 1,909,585 | 0.00 | 424,347 |
| 11 Aug 22 | Doogan Declan | Common Stock | Gift | Acquire G | No | No | 0 | 567,871 | 0.00 | 3,637,871 |
| 11 Aug 22 | Doogan Declan | Common Stock | Gift | Dispose G | Yes | No | 0 | 567,871 | 0.00 | 0 |
| 9 Jun 22 | June Sherie Almenoff | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 5,000 | 3.10 k | 5,000 |
| 9 Jun 22 | Michael H. Davidson | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 5,000 | 3.10 k | 5,000 |
| 9 Jun 22 | Doogan Declan | Stock Option Common Stock | Grant | Acquire A | No | No | 0.62 | 5,000 | 3.10 k | 5,000 |
News
Tenax Therapeutics Announces Issuance Of U.S. Patent Covering Use Of IV Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction; Shares Move Higher
22 Mar 23
Tenax Therapeutics Will Be Issued U.S. Patent Number 11,607,412 Tomorrow Titled "Levosimendan For Treating Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction"
20 Mar 23
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
13 Mar 23
12 Health Care Stocks Moving In Monday's Pre-Market Session
13 Mar 23
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
13 Mar 23
Press releases
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
22 Mar 23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
3 Feb 23
Thinking about buying stock in Carvana, Bed Bath & Beyond, Kubient, Tenax Therapeutics, or Rockwell Medical?
2 Feb 23
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
1 Feb 23